Trade setup intelligence
Charts, patterns, liquidity, and profile weighting stay together before a setup is surfaced.
Signal through the silt.
Follow market prices, charts and current catalysts without an account. When you need a decision workflow, move into ranked intelligence with data-quality checks and risk-aware review.
Automated Market Intelligence
Charts, patterns, liquidity, and profile weighting stay together before a setup is surfaced.
Market-moving headlines are normalized, scored, and matched to the stocks they can move.
Automation is gated by data quality, risk limits, and explicit confidence thresholds.
Signal Workflow
Market headlines and bars enter one data-quality boundary.
Catalysts are separated into bullish, neutral, and bearish context.
Opportunity boards blend catalyst impact with chart and risk signals.
Execution-facing actions stay behind operator and risk checks.
Current Catalysts
Source-attributed headlines captured in the last hours, each linked to the public stock and crypto pages it mentions. Browse all market news
The system only ranks opportunities when real market and catalyst data is available. Missing data produces a clear unavailable state instead of noise.
Review integrationsbiote reported Q3 2026 results with a 9.6% year-over-year revenue decline to $43.3 million, attributed to a January 2026 product recall that delayed clinic onboarding. Despite this, the company maintains full-year 2026 revenue guidance above $175 million. Management is deploying data analytics to support underperforming clinics, standardizing medical training to retain practitioners, and ramping up internal manufacturing at Xteria Health to restore gross margins, with early signs of procedure volume stabilization.
IREN stock fell 9.80% to $16.39 on November 16, 2026, as broad tech sector selling and neocloud weakness pressured shares. The decline was driven by concerns over AI industry regulation following tighter U.S. government controls on AI technology access, a $6 billion funding gap for IREN's 2027 infrastructure plan, and rising Treasury yields. Sector peers TeraWulf and Cipher Digital also declined significantly.
NextNRG announced Q3 2026 financial results with revenue rising 16.9% to $26.7 million and net loss narrowing 45.2%. However, the company faces significant headwinds including suspension from Nasdaq (now trading OTC Pink), reduced fuel gallons delivered, and gross profit decline despite revenue growth. Nine-month results showed 28.4% revenue growth but 57.4% net loss improvement, driven primarily by reduced stock-based compensation and interest expenses.
Following Jensen Huang's departure from Nvidia, the article suggests AMD may now have a leadership advantage over Nvidia. The piece examines whether investors should consider switching from Nvidia to AMD stock in light of this executive change and recent market headwinds affecting Nvidia.
Four AI chip stocks—AMD, TSMC, ASML, and Micron—have declined 18-36% from their highs and present long-term buying opportunities. AMD's data center revenue surged 97% YoY, TSMC hit monthly revenue records, ASML sees customer orders extending to 2029-2030, and Micron benefits from increasing memory demands in AI chips. The author recommends prioritizing TSMC and ASML for their stable revenue streams, with smaller positions in AMD and Micron.
Definium Therapeutics announced positive Phase 3 clinical trial results for its lead psychiatric drug DT120 in generalized anxiety disorder and major depressive disorder, with plans to file for regulatory approval in the first half of 2027. The company holds $1.05 billion in cash to fund operations through 2030 and showed early efficacy signals for pipeline expansion into autism spectrum disorder with DT402.